Arsenic trioxide as a radiation sensitizer for 131I-metaiodobenzylguanidine therapy: Results of a phase II study Academic Article uri icon

Overview

MeSH Major

  • 3-Iodobenzylguanidine
  • Adrenal Gland Neoplasms
  • Arsenicals
  • Brain Neoplasms
  • Neuroblastoma
  • Oxides
  • Paraganglioma
  • Pheochromocytoma
  • Radiation-Sensitizing Agents
  • Radiopharmaceuticals

abstract

  • (131)I-MIBG plus arsenic trioxide was well tolerated, with an adverse event profile similar to that of (131)I-MIBG therapy alone. The addition of arsenic trioxide to (131)I-MIBG did not significantly improve response rates when compared with historical data with (131)I-MIBG alone.

publication date

  • February 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4976822

Digital Object Identifier (DOI)

  • 10.2967/jnumed.115.161752

PubMed ID

  • 26742708

Additional Document Info

start page

  • 231

end page

  • 7

volume

  • 57

number

  • 2